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Expression of μ-protocadherin is negatively regulated
by the activation of the β-catenin signaling pathway in
normal and cancer colorectal enterocytes
L Montorsi1, S Parenti1, L Losi1, F Ferrarini2, C Gemelli1, A Rossi3, G Manco3, S Ferrari1, B Calabretta4,5, E Tagliafico6,7,
T Zanocco-Marani1,8 and A Grande*,1,8
Mu-protocadherin (MUCDHL) is an adhesion molecule predominantly expressed by colorectal epithelial cells which is markedly
downregulated upon malignant transformation. Notably, treatment of colorectal cancer (CRC) cells with mesalazine lead to
increased expression of MUCDHL, and is associated with sequestration of β-catenin on the plasma membrane and inhibition of its
transcriptional activity. To better characterize the causal relationship between β-catenin and MUCDHL expression, we performed
various experiments in which CRC cell lines and normal colonic organoids were subjected to culture conditions inhibiting (FH535
treatment, transcription factor 7-like 2 siRNA inactivation, Wnt withdrawal) or stimulating (LiCl treatment) β-catenin activity. We
show here that expression of MUCDHL is negatively regulated by functional activation of the β-catenin signaling pathway. This
finding was observed in cell culture systems representing conditions of physiological stimulation and upon constitutive activation
of β-catenin in CRC. The ability of MUCDHL to sequester and inhibit β-catenin appears to provide a positive feedback enforcing the
effect of β-catenin inhibitors rather than serving as the primary mechanism responsible for β-catenin inhibition. Moreover,
MUCDHL might have a role as biomarker in the development of CRC chemoprevention drugs endowed with β-catenin inhibitory
activity.
Cell Death and Disease (2016) 7, e2263; doi:10.1038/cddis.2016.163; published online 16 June 2016
Cadherins are integral membrane proteins constituting a
complex superfamily, which consists of 4100 members and
are divided into classical cadherins and protocadherins. The
latter are characterized by the presence of one or more
unconventional domains in addition to the typical cadherin-like
domains, which are responsible for the canonical function of
these proteins.1 From a structural point of view, cadherins are
composed of an extracellular portion, harboring its cadherin-
like domains through which they promote intercellular adhe-
sion, and an intra-cellular portion, through which they inhibit
cell proliferation. This effect is achieved by sequestering
β-catenin in a submembrane location, thereby preventing its
translocation to the nucleus where, in normal conditions, it
activates the transcription of growth-promoting target genes.2
Not surprisingly, as a result of these activities, cadherins exert
a recognized onco-suppressor effect that can be observed in
different cell types, depending on their expression pattern.3 In
the last decade, a novel cadherin, named μ-protocadherin
(MUCDHL) to underline the hybrid nature of its extracellular
portion, which contains four cadherin-like and three mucin-like
domains, has been isolated and characterized.4 This protein
maintains all the general features of cadherins and carries, in
its intra-cellular portion, four prolin-rich domains together with
a single PDZ domain, previously shown to bind β-catenin.
A survey of MUCDHL distribution revealed that significant
levels of its expression were exclusively detected in a couple
of anatomical sites, including colorectal mucosa.5 This
observation suggested a possible role in colorectal carcino-
genesis that was subsequently supported by experimental
results. Indeed, interaction of MUCDHL with β-catenin, which
is constitutively activated in colorectal cancer (CRC), was
confirmed and MUCDHL expression exhibited a remarkable
downregulation in 470% of CRC cases, in association with
higher proliferation indexes.6 Notably, data obtained in our
laboratory showed that treatment of CRC cells with an anti-
inflammatory drug named mesalazine (5-ASA), that is able to
inhibit β-catenin signaling in vitro and to exert anti-CRC
chemoprevention activity in vivo,7 markedly inducesMUCDHL
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expression.8 This finding might, in our opinion, reflect two
distinct explanations: (i) 5-ASA could induce MUCDHL
expression, sequester β-catenin on the cell membrane and
inhibit its signaling pathway; or (ii) 5-ASA could inhibit β-
catenin, leading to an upregulation of MUCDHL, dependent on
the fact that expression of this protein is negatively regulated
by β-catenin signaling (Supplementary Figure 1). In other
terms, upregulation of MUCDHL may represent the cause or
the effect of β-catenin inhibition, respectively. In both cases
MUCDHL would, once expressed, sequester and inhibit β-
catenin on the plasma membrane, although with different
biological consequences. To better understand the correlation
between β-catenin activity and MUCDHL expression, we
performed experiments in which the β-catenin signaling
pathway was inhibited in CRC cell lines using a chemical
inhibitor or a siRNA-based approach and showed that
MUCDHL expression is upregulated by both treatments. By
contrast, the opposite effect was observed in human colonic
organoids treated with a compound able to activate the β-
catenin signaling pathway.
Results
Downregulation of MUCDHL expression correlates with
APC mutation in sporadic CRC. An important clue
supporting the possibility that regulation of MUCDHL
expression is a downstream event of the β-catenin signaling
pathway (second hypothesis of Introduction) came from the
observation that MUCDHL downregulation always accom-
panies adenomatous polyposis coli (APC) inactivation in
CRC. In fact, immuno-histochemical data obtained in our
laboratory showed that 11 out of 21 analyzed CRC cases
were negative for MUCDHL and APC expression, whereas
the remaining exhibited a double positivity for the same
proteins (Figure 1). This finding suggests that the constitutive
activation of the β-catenin signaling pathway, determined by
mutation/inactivation of APC, is responsible for a reduced
expression of MUCDHL, implying that the latter is negatively
regulated by the former.
Treatment of CaCo2 and HCT116 CRC cell lines with a
β-catenin inhibitor leads to increased expression of
MUCDHL. To further support the hypothesis that expression
of MUCDHL is negatively regulated by active β-catenin, we
treated the CaCo2 and HCT116 CRC cell lines with the
FH535 compound, which inhibits the β-catenin pathway
through complete silencing of the β-catenin-regulated tran-
scription factor 7-like 2 (TCF4) transcription factor. Cell
counts, obtained in a preliminary dose-response experiment,
indicated that a complete inhibition of proliferation was
reached with a 30–60 μM concentration after 96 h of
treatment, in CaCo2 cells, and 15–30 μM concentration after
48 h of treatment, in HCT116 cells (Figure 2, panel a;
Supplementary Table 1 and 2). Thus, under these experi-
mental conditions, we evaluated changes in gene expression
at the mRNA and protein level, by quantitative real-time PCR
(QRT-PCR) and western blot, respectively, of MUCDHL,
E-cadherin (CDH1), previously characterized as a negative
target of β-catenin, p21waf-1, as a molecular marker of
proliferation arrest, and caudal type homeobox transcription
factor 2 (CDX2), a transcriptional activator of MUCDHL.
In the CaCo2 cell line, at the highest FH535 concentration,
transcript levels of the four analyzed genes were induced
3.4-, 2.2-, 8.6- and 1.9-fold, respectively, with virtually all
variations exhibiting statistical significance (Figure 2, panel b;
Supplementary Table 3). A similar response was observed in
the HCT116 cell line where the induction was 3.2, 5.0, 11.5
and 10.3 fold, although the changes did not reach statistical
significance (Figure 2, panel b; Supplementary Table 4).
As expected, protein levels of TCF4 were strongly down-
regulated in both FH535-treated CRC cell lines and, in
general, gene expression changes detected by western blot
were more pronounced than those observed by QRT-PCR
(Figure 2, panel c). Indeed, at the highest FH535 concentra-
tion, the upregulation of MUCDHL and CDX2 proteins was
11.3 and 6.9 times in CaCo2 cells and 3.0 and 2.5 times in
HCT116 cells.
Together, this analysis suggests that the β-catenin signaling
pathway exerts a negative regulation on the expression of
MUCDHL and CDX2.
Transfection of CaCo2 and HCT116 CRC cell lines with an
anti-TCF4-specific siRNA leads to increased expression
of MUCDHL. To confirm the data obtained with the FH535
compound using a more specific approach, the same cell
lines were transfected with a mix of three TCF4 siRNA
oligonucleotides and the effects of this treatment on gene
expression were evaluated by QRT-PCR and western
blotting.
Transfection with the anti-TCF4 siRNA induced an appar-
ently modest downregulation of its target TCF4 mRNA of
32 and 50% in CaCo2 and HCT116 cells, respectively, as
assessed by QRT-PCR (Figure 3, panel a; Supplementary
Table 5 and 6); however, western blot analysis indicated a
complete disappearance of the corresponding protein in both
cell lines (Figure 3, panel b), probably reflecting the combined
effect of increased RNA degradation and translation inhibition
induced by the anti-TCF4 siRNA on its target.
QRT-PCR analysis revealed that all other tested genes
were upregulated upon TCF4 silencing, almost always with
statistically significant P-values (Figure 3, panel a; Supple-
mentary Table 5 and 6). Among them, MUCDHL exhibited the
most pronounced variation, showing a 1.9-fold increase in
CaCo2 cells and 3.4 increase in HCT116 cells. The results
of western blot analysis confirmed those of QRT-PCR
(Figure 3, panel b).
Withdrawal of Wnt stimulation in human colonic orga-
noids induces MUCDHL expression. To further confirm the
data obtained in CaCo2 and HCT116 cell lines in a primary
cell context, we generated in our laboratory the experimental
model of human colonic organoids previously described by
Clevers and collaborators.9 Inhibition of the β-catenin path-
way was then mimicked through scalar reduction of the Wnt
ligand that was added to the culture at a standard dose, and
at one-fifth and one-tenth concentrations. A control sample in
which organoids were induced to differentiate was also set up
using, besides the 90% Wnt reduction, complete withdrawal
of other β-catenin agonists such as PGE2. In addition to the
β-catenin activation inhibits MUCDHL expression
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genes tested above, QRT-PCR analysis included the Keratin-
20 gene, as a marker of enterocyte differentiation, and the
Met and CD44 genes, as direct targets of the β-catenin
signaling pathway. As shown in Figure 4a and Supplementary
Table 7, mRNA expression of MUCDHL, Keratin-20, E-cad-
herin, CDX2 and p21waf1 genes, showed a gradual increase
from standard culture to differentiation conditions, reaching
mean values of 3.4, 3.2, 1.6, 2.5, 3.8, respectively. The Met
and CD44 genes showed an exactly inverted trend, exhibiting
a 21 and 73% decrease, respectively, of their mRNA
expression. Most comparisons were statistically significant
(Figure 4, panel a; Supplementary Table 7). Inhibition
of the β-catenin signaling also affected the morphology of
organoids, revealing a collapsed shape evidenced by
light-inverted microscope examination followed by the
assessment of circularity values with the ImageJ software
(0.88±0.007 U of control versus 0.79±0.012 U of differen-
tiated samples, Po0.0001) (Figure 4, panels b and c,
Supplementary Table 10).
Treatment of human colonic organoids with LiCl inhibits
MUCDHL expression. The experimental advantage of
human colonic organoids is also represented by the
possibility to analyze the effects of inducible stimulation of
β-catenin signaling, unlike the CRC cell lines where this
pathway is constitutively activated as consequence of APC
mutation. This condition was obtained upon treatment with 5
or 10 mM LiCl, which is known to inhibit the GSK3β enzyme,
leading to stabilization and activation of β-catenin. Then,
QRT-PCR analysis was carried out as described in the
previous experiment. With the only exception of the Met gene,
the results observed were, as expected, opposite to those
elicited by withdrawal of the β-catenin agonists. In fact, at the
highest LiCl concentration, there was a 46% decrease for
MUCDHL, 61% for Keratin-20, 48% for E-cadherin, 60% for
CDX2 and 42% for p21waf1, whereas, under the same
conditions, the CD44 gene showed a 2.6-fold increase of its
transcript levels (Figure 5, panel a; Supplementary Table 8).
All variations were statistically significant. In agreement
with its activity on the β-catenin pathway, treatment with
LiCl determined a positive effect on the proliferation rate of
organoids demonstrated by a more pronounced thickness of
their peripheral lining, observed again through a light-inverted
microscope and measured with the ImageJ software
(50.2± 2.7 μm of LiCl treated versus 23.7±1.5 μm of
control samples, Po0.0001) (Figure 5, panels b and c;
Supplementary Table 11).
CDX2 silencing abolishes MUCDHL upregulation
induced by 5-ASA treatment. In the studies presented
here, variations of MUCDHL expression in response to
modulators of β-catenin activity, correlate with those of the
CDX2 transcription factor, suggesting its involvement in the
regulation of MUCDHL levels. To verify this possibility, the
CaCo2 cells were transfected with a scrambled control siRNA
or with a mix of three anti-CDX2 siRNAs for 12 h, and then
cultured for an additional 4-day period in the absence or
presence of 20 mM 5-ASA. The decision to use this
compound was based on its anti-CRC chemoprevention
capacity, previously related to its ability to inhibit β-catenin
activity and induce MUCDHL expression.
Figure 1 (a) Table summarizing the results of the immuno-histochemical analysis of APC and μ-protocadherin (MUCDHL) protein levels in 21 CRC samples; + and −
indicate presence or absence of the analyzed protein, respectively. (b) Immuno-histochemical analysis of two representative CRC cases exhibiting a double positive (APC
+/MUCDHL+) (CRC +/+) or a double negative (APC− /MUCDHL− ) (CRC − /− ) expression pattern. Positivity appears as a dark staining; cell nuclei were counterstained with
hematoxylin
β-catenin activation inhibits MUCDHL expression
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As expected, CaCo2 cells transfected with control siRNA
and exposed to 5-ASA, exhibited a 2.8-and 3.4-fold increase
of CDX2 and MUCDHL mRNA, respectively, detected by
QRT-PCR (Figure 6, panel a, Supplementary Table 9).
Instead, transfection of the anti-CDX2 siRNAs resulted in
~ 50% reduction of these values returning them approximately
to their basal level.Western blot analysis, carried out under the
same experimental conditions, showed that CDX2 silencing
Figure 2 Effects of FH535 treatment in the CaCo2 and HCT116 CRC cell lines. (a) FH5353 causes a dose- and time-dependent inhibition of cell proliferation. Cells were
treated with the indicated concentrations of FH535 and counted after 24, 48, 72 and 96 h (x axis). Number of cell expansions are reported on y axis as mean values obtained from
three independent experiments. (b) FH535 induces upregulation of μ-protocadherin (MUCDHL), E-cadherin (CDH1), p21waf1 and CDX2 transcripts. Cells were treated with the
indicated doses of FH5353 and analyzed by QRT-PCR after 96 h for CaCo2 and 48 h for HCT116 cells. Mean variations of mRNA expression levels, deriving from three
independent experiments, are reported in the y axis as relative fold-change (relative quantity). Results are represented as mean±S.E.M. values and asterisks indicate
statistically significant results (Po0.05). (c) Western blot analysis following treatment with FH535 shows a decreased expression of TCF4 protein and a concomitant increase of
MUCDHL and CDX2 protein expression. Cells were treated with the indicated doses of FH535 and analyzed after 96 h for CaCo2 and 48 h for HCT116 cells. This analysis was
performed on nuclear and cytoplasmic extracts and normalized with actin. Analyzed proteins and their molecular weights are indicated on the left and on the right, respectively
β-catenin activation inhibits MUCDHL expression
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was complete and variations of MUCDHL protein were
consistent with those of its transcript (Figure 6, panel b).
Discussion
Metastasis is the result of a complex process by which cancer
cells detach from the initial tumor mass and acquire the
capacity to migrate to distinct anatomical sites where they give
rise to one or more secondary tumors. Reduced expression of
cadherins is critically important in this process, owing to their
role in promoting cell–cell adhesion in normal conditions.10
E-cadherin is considered the main adhesion molecule in
epithelial tissues and loss of its expression, when observed,
has been ascribed to epigenetic alterations (gene promoter
hypermethylation) or to transcriptional repression mediated by
Snail family members.11 These proteins can be divided into
two subgroups that are able to repress E-cadherin expression
directly, binding to its promoter region (Snail, Slug), or
indirectly, with a different mechanism (Twist, ITF2). Interest-
ingly, a number of reports have highlighted the ability of the
β-catenin pathway to activate Snail family transcription
repressors.12,13 This effect is reached through a couple of
distinct molecular mechanisms: (i) activation of Snail and Slug
as consequence of Wnt-induced GSK3β inhibition, leading to
their stabilization and nuclear translocation; and (ii) direct
transcriptional activation of Twist and ITF2 by β-catenin/
TCF4.14–17 However, experimental evidence supporting the
existence of a molecular cascade, linking β-catenin signaling
to Snail proteins and to E-cadherin expression, has almost
exclusively been obtained in breast cancer and its normal
counterpart.14,15 On the other hand, loss of E-cadherin
expression is rarely detected in CRC where downregulation
of MUCDHL is, instead, a common event.6 In this report, we
clearly demonstrated, for the first time, that MUCDHL
expression is negatively regulated by β-catenin signaling.
This finding was obtained in epithelial cancer cells aswell as in
normal colon enterocytes, represented by CRC cell lines and
colonic organoids, respectively. Moreover, treatments inhibit-
ing the entire β-catenin pathway (Wnt deprivation), or GSK3β
activity (LiCl), or β-catenin-dependent transcription (FH535,
siRNA), all affected MUCDHL expression, suggesting that this
effect could be ascribed to a transcription repressor induced
by β-catenin, such as the ITF2 member of the Snail family.
Computational analysis of ‘Chip-Seq’ data contained inside
the ENCODE project database, allowed us to retrieve, among
Snail family proteins able to bindMUCDHL promoter, the Zeb1
repressor. However, QRT-PCR analysis on HCT116 cells
transfected with an anti-TCF4 siRNA oligonucleotide or
treated with the FH535 compound, failed to detect an
upregulated expression of genes coding for either ITF2 or
Zeb1, suggesting that they do not have an important role in
β-catenin regulation of MUCDHL expression (data not shown).
Figure 3 Inhibition of β-catenin pathway induced by transfection of an anti-TCF4-specific siRNA in CaCo2 and HCT116 cell lines. (a) siRNA-mediated silencing of TCF4
results in the induction of MUCDHL, CDX2, and p21waf1 transcripts. Cells were transfected with a scrambled siRNA (Cont. siRNA) or with a mix of siRNA against TCF4 (TCF4
siRNA) and analyzed after 72 h by QRT-PCR. Data are presented as in Figure 2, panel b. Results are represented as mean±S.E.M. values and asterisks indicate statistically
significant results (Po0.05). (b) Western blot analysis confirming the results of the QRT-PCR reactions. This analysis was performed on cell samples under the same
experimental conditions and the results presented as explained in Figure 2, panel b
β-catenin activation inhibits MUCDHL expression
L Montorsi et al
5
Cell Death and Disease
Conversely, variations of MUCDHL expression, in response to
stimuli modulating the activity of the β-catenin pathway,
consistently showed a direct correlation with those of the
transcription activator CDX2. A previous report has
demonstrated that the transcription of MUCDHL gene is
directly controlled by this transcription factor through a specific
DNA-binding site in its promoter region.18 Taken together,
these observations allow us to speculate that the negative
Figure 4 Deprivation of WNT3a in culture medium of human colonic organoids induce the mRNA expression of MUCDHL and CDX2. (a) Colonic organoids were cultured in
the presence of gradually reduced concentrations of WNT3a (1/5 and 1/10 of the standard concentration) or under differentiation-inducing conditions characterized by the
complete withdrawal of all β-catenin agonists from culture medium. QRT-PCR analysis was performed after 72 h and the mean values obtained by four independent experiments
presented as in previous figures. Results are represented as mean± S.E.M. values and asterisks indicate statistically significant results (Po0.05). (b) Representative bright-field
image of colonic organoids grown under standard (Cont.) or differentiation conditions. (c) Analysis of circularity performed on colonic organoids cultured under standard (Cont.) or
differentiation conditions. The dot plot shows the results of two independent experiments represented as mean± S.E.M. (***Po0.0001)
β-catenin activation inhibits MUCDHL expression
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regulation of MUCDHL expression by β-catenin might be
actually exerted via CDX2, through a transcription repressor
that remains to be identified. This hypothesis is supported by
the evidence that CDX2 silencing interferes with the capacity
of 5-ASA, a β-catenin inhibitor with anti-CRC chemopreven-
tion activity, to upregulate MUCDHL expression. In aggregate,
our data suggest that the silencing of MUCDHL expression
observed in CRC is consequent to the constitutive activation of
the β-catenin pathway, which is typical of these tumors. The
development of compounds able to restore the expression of
MUCDHL, thus stimulating its anti-tumor (anti-proliferative and
anti-metastatic) properties, opens important possibilities for
chemoprevention and/or therapy of CRC. The rationale
underlying this pharmacological approach also implies a
possible role of MUCDHL as biomarker to estimate the extent
to which these compounds may be effective. The negative
Figure 5 Stimulation of the β-catenin signaling pathway in human colonic organoids, with a GSK3β inhibitor, reduces MUCDHL and CDX2 mRNA expression. (a) Colonic
organoids were treated with the indicated amount of LiCl and analyzed by QRT-PCR 72 h later. Mean values obtained from four independent experiments are shown as in
previous figures. Results are represented as mean±S.E.M. values and asterisks indicate statistical significance (Po0.05). (b) Representative bright-field image of colonic
organoids grown under standard conditions (Cont.) or in presence of LiCl 10 mM. (c) Analysis of epithelial lining thickness of colonic organoids grown under standard conditions
(Cont.) or in presence of LiCl. The dot plot shows the results of two independent experiments represented as mean± S.E.M. (***Po0.0001)
β-catenin activation inhibits MUCDHL expression
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effect on MUCDHL expression exerted by constitutive β-
catenin activation observed in CRC may be simply the
consequence of a physiological mechanism already operating
in normal colon enterocytes. Based on the capacity of
MUCDHL to sequester and inhibit β-catenin at the cell
membrane, this biological activity might represent the result
of a positive feedback amplifying the final effects of stimuli that
either activate or inhibit the β-catenin signaling pathway. The
inverse correlation existing along the axis of colon crypt
between the nuclear localization of β-catenin (observed at the
bottom) and the expression of MUCDHL (detected on the top),
in our opinion, provides further support for this hypothesis.
Materials and Methods
Cell cultures and treatments. HCT116 and CaCo2 cells were obtained
from ATCC (Rockville, MD, USA) and cultured in DMEM supplemented with 10%
fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA), 2 mM-Glutamine
(EuroClone, Devon, UK) and 100 U/ml Penicillin/Streptomycin (EuroClone).
FH535 was purchased from Sigma-Aldrich and dissolved in DMSO at a 30 mM
concentration. Treatment with this compound was carried out at times and
concentrations indicated in Results and Figures. Control cells were exposed to an
equivalent amount of vehicle. Cell counts were performed at 24 h intervals using the
Trypan blue exclusion assay. All the experiments were repeated at least three times.
siRNA transfection. Experiments of mRNA silencing were conducted
transfecting a mix of three different siRNA oligonucleotides directed against TCF4
or CDX2 (Sigma-Aldrich) at a concentration of 100 nM with the RNAiMAX reagent
(Invitrogen, Carlsbad, CA, USA). The transfection efficiency of CaCo2 cells was
potentiated using the reverse transfection procedure.
RNA extraction and QRT-PCR. Cells undergoing RNA extraction were
trypsinized, washed once in PBS (EuroClone), re-suspended in lysis buffer and
extracted with Qiagen total RNA purification kits (Qiagen, Valencia, CA, USA),
following the manufacturer instructions. Total RNA was quantified using a NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and 100 ng
were used to synthesize cDNA with the High Capacity cDNA Retro-transcription Kit
(Invitrogen). Quantitative Real-Time PCR (QRT-PCR) was then conducted using an
ABI PRISM 7900 detection system (Applied Biosystems). All primers and probes
used for mRNA amplification were designed by Applied Biosystems. Each cDNA
sample was run in triplicate using the Taqman Universal PCR Master Mix
(Invitrogen) and glyceraldehyde-3-phosphate dehydrogenase was used as an
endogenous control. Quantification of RT-PCR signals was performed using the Ct
relative quantification method. This procedure calculates the relative changes in
gene expression of the target gene normalized with an endogenous control and
compared with a calibrator sample.
Protein extract preparation and western blot analysis. Preparation
of nuclear and cytoplasmic protein extracts and western blot analysis were carried
out as previously described.19 In brief, electrophoresis was performed on sodium
dodecyl sulfate polyacrylamide gel electrophoresis followed by electro-blotting to
nitrocellulose sheets. Blotted membranes were pre-blocked with a solution
containing 5% nonfat milk (Regilait, Saint Martin-Belle-Roche, France) in 0.05%
TBSTand incubated with a primary antibody specific for each analyzed protein, and
with a common secondary antibody conjugated to horseradish peroxidase.
The following primary antibodies and the respective dilutions were used for
western blot analysis: mouse anti-MUCDHL monoclonal antibody (MoAb) (A-11,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:500 in TBST 3% milk; rabbit
anti-CDX2 MoAb (ab76541 Abcam, Cambridge, UK) 1:1000 in TBST 1% milk; mouse
anti-E-Cadherin MoAb (610181 BD Transduction Laboratories, San Jose, CA, USA)
1:1000 in TBST 5% milk; rabbit anti-TCF4 MoAb (C48H11 Cell Signaling Technology,
Danvers, MA, USA) 1:1000 in TBST 5% BSA.
Expression of actin was also evaluated with a mouse pan-actin MoAb (Millipore
Corporation, Billerica, MA, USA) to normalize the protein content of the various
analyzed samples.
As secondary antibodies, a goat anti-mouse IgG (Santa Cruz Biotechnology) or a
goat anti-rabbit IgG (Cell Signaling Technology), both conjugated with horseradish
peroxidase, were used respectively at 1:10 000 and 1:15 000 dilutions. Detection of
western blot signals was carried out using the Westar EtaC enhanced chemi-
luminescent substrate (Cyanagen S.r.l., Bologna, Italy). Densitometric analysis was
accomplished using the ImageJ Software.
Culture of colonic organoids. Samples of normal colon mucosa were
obtained from the Bio-Bank of Modena (BBM) (C.O.M. Via del Pozzo 71 41124,
Modena, Italy). After surgical resection, the cancerous mucosa was used for
histopathological analysis and for the BBM sampling, whereas a small fragment of
healthy tissue was used for experiments and the rest was discharged.
Culture of human colonic organoids was carried out as described by Peter Jung.9 In
brief, colonic crypts were separated from the underlying stroma through chelating
agents, washed thoroughly and embedded in matrigel. After matrigel polymerization,
the crypts were overlaid with complete growth medium which was composed of HAM’s
F12 supplemented with: antibiotics, 5% FBS (Sigma-Aldrich), Glutamax 1 × (Life
Technologies), 10 mM HEPES, N-2 Supplement (Life Technologies) 1 × , B-27
supplement without retinoic acid (Life Technologies) 1 × , 10 mM Nicotinamide (Sigma-
Aldrich), 1 mM N-Acetyl-L-cysteine (Sigma-Aldrich), 1 μg/ml RSPO1 (R&D System,
McKinley Place NE, Minneapolis), 100 ng/ml human EGF (R&D System), 100 ng/ml
human Noggin (R&D System), 1 μg/ml Gastrin I (Sigma), 100 ng/ml WNT3a (R&D
System), 500 nM LY2157299 (Axon MedChem, Groningen, The Netherlands), 10 μM
SB202190 (Sigma), and 0.01 μM PGE2 (Sigma). For the first 48–72 h of culture, the
crypts were left in complete growth medium, with the addition of the Rock inhibitor
Y-27623 (10 μM Sigma-Aldrich), in order to allow the formation of organoids.
In the following days, they were subjected to various treatments. Incubation with
LiCl (Sigma) was conducted at 5 and 10 mM concentrations of the compound.
Reduced levels of WNT3a were obtained lowering its concentration to 20 or 10 ng/ml,
corresponding to 1/5 and 1/10 of the standard amount. The differentiation condition
was achieved in complete absence of WNT3A, PGE2 and SB202190.
After 72 h of treatment, organoids were collected from matrigel with Cell
Dissociation Solution (BD Transduction), washed with cold PBS and RNA was
extracted as previously described.
Morphological analysis of organoids was conducted using the ImageJ software on
pictures obtained by light-inverted microscope examination. Circularity was assessed
outlining their outer edge with the freehand selection tool and expressed as Units (U)
Figure 6 Transfection of CaCo2 cells with an anti-CDX2 siRNA interferes with
upregulation of μ-protocadherin expression induced by stimulation with 5-ASA.
(a) CaCo2 cells were transfected with a scrambled siRNA (Cont. siRNA) or a mix of
anti-CDX2 siRNAs (CDX2 siRNA) and stimulated with 5-ASA to induce
μ-protocadherin expression. The effect determined on the expression of CDX2
and MUCDHL mRNAs was then analyzed by QRT-PCR. Results are represented as
mean± S.E.M. values and asterisks indicate statistically significant results
(Po0.05). (b) The effect determined on the expression of the same genes at the
protein level was evaluated by western blot analysis. Data were presented according
to the same modalities of the previous figures
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(1 U representing the value generated by a perfect circle), whereas the thickness of
their epithelial lining was measured using the straight line selection tool, and
expressed in micrometers (μm).
Statistical analysis. All experiments were repeated at least three times,
unless otherwise stated, and the results presented in terms of mean± S.E.M.
values. Pairwise comparisons were carried out using the Student’s t-test procedure.
Results of statistical analysis were considered significant at P-values o0.05
(*o0.05, **o0.001, ***o0.0001).
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